Evidence map›Paper›PMID 42159577›Full record

ArticleThe oncologist2026

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

Sara Elena Rebuzzi, Aruni Ghose, Sarah Rudman, Balaji Venugopal, Kate Young, Ricky Dylan Frazer, Olubukola Ayodele, Mark Stares, Brent O'Carrigan, Waqas Ali and 59 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

69 authors.

Sara Elena RebuzziMedical Oncology Unit 2, Ospedale Molinette, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, 10126, Italy.
Aruni GhoseBarts Cancer Centre, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.
Sarah RudmanCancer Centre at Guy's, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom.
Balaji VenugopalBeatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, G12 0YN, United Kingdom.
Kate YoungDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom.
Ricky Dylan FrazerVelindre Cancer Centre, Velindre University NHS Trust, Cardiff, CF14 2TL, United Kingdom.
Olubukola AyodeleLeicester Cancer Research Centre, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, United Kingdom.
Mark StaresEdinburgh Cancer Centre, NHS Lothian, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom.
Brent O'CarriganDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom.
Waqas AliDepartment of Oncology, United Lincolnshire Hospitals NHS Trust, Lincoln, LN2 5QY, United Kingdom.
John McGraneSunrise Oncology Centre, Royal Cornwall Hospitals NHS Trust, Cornwall, TR1 3LJ, United Kingdom.
Ankit JainDeanesly Centre for Cancer Services, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, United Kingdom.
Ondrej FialaDepartment of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University Prague, 323 00, Czech Republic.
Vishwani ChauhanBarts Cancer Centre, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.
Agnieszka MichaelRoyal Surrey Cancer Centre, Royal Surrey NHS Foundation Trust, Guildford, GU2 7XX, United Kingdom.
Anjali ZarkarDepartment of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.
Gaurav KapurDepartment of Oncology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, NR4 7UY, United Kingdom.
Natalie CharnleyRosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, PR2 9HT, United Kingdom.
Mehran AfsharDepartment of Oncology, St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, United Kingdom.
Salil VengalilCancer Centre, Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust, Stoke on Trent, ST4 6QG, United Kingdom.
Caroline FordeNorthern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7JL, United Kingdom.
Janet BrownWeston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2SJ, United Kingdom.
Yüksel ÜrünDepartment of Medical Oncology, Ankara University Cancer Research Institute, Ankara, 06590, Turkey.
Diletta BianchiniKent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, ME16 9QQ, United Kingdom.
Amit BahlBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, BS2 8ED, United Kingdom.
Narayanan SrihariLingen Davies Cancer Centre, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, SY3 8XQ, United Kingdom.
Fabrizio Di CostanzoTranslational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.ORCID 0009-0001-2173-8245
Benjamin SmalleyDepartment of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, United Kingdom.
Joanne ParkesWorcestershire Oncology Centre, Worcestershire Acute Hospitals NHS Trust, Worcester, WR5 1DD, United Kingdom.
Simon CrabbDepartment of Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom.
Naveen VasudevLeeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom.
Alexandr PoprachDepartment of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, 656 53, Czech Republic.
Nicholas BrownCancer Centre at Guy's, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom.
Lijo JamesBeatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, G12 0YN, United Kingdom.
Sophia HaywoodDepartment of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom.
Jose TapiaVelindre Cancer Centre, Velindre University NHS Trust, Cardiff, CF14 2TL, United Kingdom.
Anupama VijayLeicester Cancer Research Centre, University Hospitals of Leicester NHS Trust, Leicester, LE1 5WW, United Kingdom.
Jane ParryEdinburgh Cancer Centre, NHS Lothian, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom.
Michael CheungDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom.
Ishika MahajanDepartment of Oncology, United Lincolnshire Hospitals NHS Trust, Lincoln, LN2 5QY, United Kingdom.
Niall O MoonSunrise Oncology Centre, Royal Cornwall Hospitals NHS Trust, Cornwall, TR1 3LJ, United Kingdom.
Ritika AbrolDeanesly Centre for Cancer Services, The Royal Wolverhampton NHS Trust, Wolverhampton, WV10 0QP, United Kingdom.
Michaela TkadlecováDepartment of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University Prague, 323 00, Czech Republic.
Yamin Shwe Yee SoeRoyal Surrey Cancer Centre, Royal Surrey NHS Foundation Trust, Guildford, GU2 7XX, United Kingdom.
Anum ZarghamDepartment of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.
Michelle SmithDepartment of Oncology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, NR4 7UY, United Kingdom.
Sophie AshleyRosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, PR2 9HT, United Kingdom.
Orla HardyDepartment of Oncology, St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, United Kingdom.
Grisma PatelDepartment of Oncology, St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, United Kingdom.
Kyaw Kyaw TunCancer Centre, Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust, Stoke on Trent, ST4 6QG, United Kingdom.
Emma JohnstonNorthern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7JL, United Kingdom.
Abdullah SarwerWeston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2SJ, United Kingdom.
Hatice BölekDepartment of Medical Oncology, Ankara University Cancer Research Institute, Ankara, 06590, Turkey.
Roshani ShresthaKent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, ME16 9QQ, United Kingdom.
Amarnath ChallapalliBristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, BS2 8ED, United Kingdom.
James MeeganLingen Davies Cancer Centre, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, SY3 8XQ, United Kingdom.
Shobana AnpalakhanDepartment of Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom.
Francesco BuonoLeeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom.
Eva KolarikovaDepartment of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, 656 53, Czech Republic.
David Ka-Wai LeungDepartment of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
Veronica MurianniS.C. Oncologia, Ospedale "Borea" di Sanremo, ASL1 Imperiese, Sanremo, 18038, Italy.
Fabio CatalanoS.C. Oncologia, Ospedale "Borea" di Sanremo, ASL1 Imperiese, Sanremo, 18038, Italy.
Davide BimbattiOncology Unit 1, Istituto Oncologico Veneto-IOV IRCCS, Padova, 35128, Italy.
Sebastiano ButiMedical Oncology Unit, University Hospital of Parma, Parma, 43126, Italy.
Alessio SignoriDepartment of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, 16132, Italy.ORCID 0000-0001-6289-9144
Giuseppe FornariniMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy.
Pasquale RescignoTranslational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.
Jeremy Yuen Chun TeohDepartment of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
Giuseppe Luigi BannaFaculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2DT, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffective risk stratification is essential for guiding treatment decisions in patients with metastatic renal cell carcinoma (mRCC). The Meet-URO score is a novel prognostic model that integrates the International Metastatic RCC Database Consortium (IMDC) criteria with neutrophil-to-lymphocyte ratio (NLR) and the presence of bone metastases. Developed in the immunotherapy era, it has demonstrated superior prognostic accuracy compared to the IMDC score across various clinical settings and treatment strategies. Its validation in the context of first-line immune-based combinations has been awaited.

methodsExternal validation of Meet-URO was performed using a large retrospective real-world cohort of mRCC patients treated with first-line immune-based combinations. Secondary analyses included a comparison with the IMDC score for predicting overall survival (OS) and progression-free survival (PFS). Additionally, restricted mean survival time (RMST) was assessed.

resultsA total of 1,418 patients were included in the analysis: 54% received ICI-ICI regimen (nivolumab plus ipilimumab), while 46% received the ICI-TKI combination. At baseline, 52.5% of patients had an NLR ≥ 3.2, and 32% had bone metastases. After a median follow-up of 26.8 months, the median OS and median PFS were 34.7 and 11.3 months, respectively. Meet-URO demonstrated effective prognostic stratification, identifying patient groups with markedly different outcomes (median OS 11.5-51.4 months; 3-year OS 26-66%; RMST 20.0-42.8 months). Compared to IMDC, Meet-URO showed a significantly better OS (c-index 0.675 vs 0.643; Δc = 0.032, P < .001) and PFS (c-index 0.60 vs 0.58; P < .001) prediction performance.

conclusionsMeet-URO demonstrated robust prognostic accuracy. Its integration into routine clinical practice and use as a stratification factor in clinical trials may support more personalized treatment strategies and enhance clinical trial design.

Indexed as

Carcinoma, Renal CellImmunotherapyKidney NeoplasmsAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective Studiesfirst lineimmune-combinationsimmunotherapymetastatic renal cell carcinomaprognosticscore

Identifiers

PMID42159577
PMCPMC13296786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.